ImmuPharma plc (IMM.L)

2,2050 -0,0350 (-1,56%) Alla chiusura: 03:55PM BST

ImmuPharma plc

1 Bartholomew Close
London EC1A 7BL
United Kingdom
44 20 7206 2650
https://www.immupharma.co.uk

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 13

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Timothy Paul McCarthy XIV, FCCA, M.B.A., MBA	Chairman & CEO	106,5k	N/D	1956
Dr. Timothy Gary Franklin M.B.A., Ph.D.	COO & Director	92,5k	N/D	1964
Ms. Lisa Baderoon	Head of Investor Relations & Non Executive Director	48k	N/D	1966
Dr. Jean-Marie Geiger PharmD, MD	Head of Clinical Development	N/D	N/D	N/D
Dr. Laura Mauran-Ambrosino Ph.D.	Chief Scientific Officer of ImmuPharma Biotech	N/D	N/D	N/D
Ms. Lara E. Sucheston-Campbell	Head of Clinical & Medical Affairs	N/D	N/D	N/D
Dr. Sébastien R. Goudreau Ph.D.	CEO of ImmuPharma Biotec & Director	N/D	N/D	1981

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in GBp.

Descrizione

ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease. Its other product candidates include BioAMB, a peptide-based drug for the treatment of Amphotericin-B formulations, a fungal infection caused by the aspergillus family of fungi; and BioCin, a peptide-based antibacterial drug used in high medical need cases and in last line of defense. The company has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of a peptide technology platform for treating diabetes with glucagon-like peptide -1 agonists, as well as development of peptides as glucagon antagonists to treat type I and type II diabetes; and license and development agreement with Avion Pharmaceuticals LLC. ImmuPharma plc was founded in 1999 and is headquartered in London, the United Kingdom.

Governance aziendale

L'ISS Governance QualityScore di ImmuPharma plc al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.